# Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone

> **NCT04167514** · PHASE3 · COMPLETED · sponsor: **CSL Behring** · enrollment: 136 (actual)

## Conditions studied

- Graft Versus Host Disease (GVHD)

## Interventions

- **BIOLOGICAL:** Alpha-1 antitrypsin (AAT)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04167514
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-09
- **Primary completion:** 2023-09-11
- **Final completion:** 2024-06-26
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2025-08-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04167514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04167514, "Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT04167514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*